Related Experiment Video
Updated: Aug 1, 2026

Quantification of Colonic Stem Cell Mutations
Published on: September 25, 2015
Diversity in expression of glucose-6-phosphate dehydrogenase deficiency in females
Y M Abdulrazzaq1, R Micallef, M Qureshi
1Department of Paediatrics, Faculty of Medicine and Health Sciences, United Arab Emirates University.
Insights
Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects 9.1% of infants in the UAE, with the Mediterranean mutation being most common. This study investigated G6PD deficiency prevalence, mutations, and inheritance patterns in the UAE population.
Area of Science:
- Genetics
- Biochemistry
- Public Health
Background:
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited red blood cell disorder.
- Understanding its prevalence and genetic basis is crucial for public health initiatives.
Purpose of the Study:
- To determine the prevalence of G6PD deficiency in the United Arab Emirates (UAE).
- To identify common G6PD mutations within the UAE population.
- To investigate inheritance patterns of G6PD deficiency in affected families.
Main Methods:
- Screening of newborns and infants for G6PD deficiency at Tawam Hospital, UAE.
- Genetic analysis of G6PD mutations in deficient individuals and their families.
- Assessment of inheritance patterns in 27 families with G6PD deficiency.
Main Results:
- A prevalence of 9.1% for G6PD deficiency was found among 8198 infants screened.
- Males (15%) showed a higher prevalence than females (5%).
- The nt563 Mediterranean mutation was predominant, with the nt202 African mutation identified in one family.
Conclusions:
- G6PD deficiency is prevalent in the UAE, primarily associated with the Mediterranean mutation.
- The study suggests potential genetic factors contributing to G6PD manifestation in females.
- Consanguinity did not appear to be a significant factor in the observed inheritance patterns.
Abstract:
The aims of this study were to determine the prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency in the United Arab Emirates (UAE), to describe the different mutations in the population, to determine its prevalence, and to study inheritance patterns in families of G6PD-deficient individuals. All infants born at Tawam Hospital, Al-Ain, UAE from January 1994 to September 1996 were screened at birth for their G6PD status. In addition, those attending well-baby clinics during the period were also screened for the disorder. Families of 40 known G6PD-deficient individuals, selected randomly from the records of three hospitals in the country, were assessed for G6PD deficiency. Where appropriate, this was followed by definition of G6PD mutations. Of 8198 infants, 746 (9.1%), comprising 15% of males and 5% of females tested, were found to be G6PD deficient. A total of 27 families were further assessed: of these, all but one family had the nt563 Mediterranean mutation. In one family, two individuals had the nt202 African mutation. The high manifestation of G6PD deficiency in women may be due to the preferential expression of the G6PD-deficient gene and X-inactivation of the normal gene, and/or to the presence of an 'enhancer' gene that makes the expression of the G6PD deficiency more likely. The high level of consanguinity which, theoretically, should result in a high proportion of homozygotes and consequently a higher proportion of females with the deficiency, was not found to be a significant factor.
Related Concept Videos
Pedigree Analysis
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Inborn Errors of Metabolism
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type I Diabetes III: Clinical Manifestations
Hyperglycemia

